News Release No: 15-10

Trading symbols: TSX-V - NEX: CIP.H

Frankfurt: BP4

Canadian International Pharma Corp. Announces Exclusive Distribution Agreement for Dubai Market

West Vancouver, British Columbia, September 28, 2015 – Canadian International Pharma Corp. (the "Company" or "CIPC") is pleased to announce that it has entered in an exclusive distribution agreement (the "Agreement") with Everhealth Natural Vitamin Company ("Everhealth") to distribute Everhealth's vitamin products to the Dubai market, which is the most populous city in the United Arab Emirates ("UAE").

"We are very excited about this new business relationship and especially about the opportunity to distribute Everhealth's premium products. We look forward to working with our potential customers in Dubai to introduce the Everhealth products and to potentially broaden the brand's presence in the UAE and Western Asia," said Mr. Mack Payravi, President of Canadian International Pharma Corp. "As part of our growth strategy, we will continue to work towards establishing similar distribution agreements with Canadian and US neutraceuticals manufacturers."

Under the Agreement with Everhealth, CIPC will manage marketing, promotion, and sales of the Everhealth brand of products in the Dubai market. Everhealth produces a line of premium products, including basic essential vitamins of the finest ingredients that the body needs, as well as formulations for specific needs such as preventative health concerns. The Agreement is for an initial term of one year with automatic renewals, subject to certain minimum purchase commitments that the Company believes are readily attainable.

About Everhealth

Everhealth Natural Vitamin Company produces a line of premium products, including basic essential vitamins of the finest ingredients that the body needs, as well as formulations for specific needs such as preventative health concerns. Everhealth has a strong product presence both domestically and internationally. Everhealth has been exporting vitamins and nutritional supplements to Canada, Turkey, Russia, Norway, Jordan, Pakistan, Azerbaijan, Kuwait, Yeman, Korea, China, Hong Kong, Mongolia, Japan, and Vietnam. Everhealth also provides private labeling for other companies. Everhealth is committed to providing only the finest nutritional products to serve consumers' daily needs and to providing new and unique supplements that reflect the current understanding in nutritional science and research.

About CIPC

Canadian International Pharma Corp ("CIPC") intends to become a multi-faceted generic drug manufacturing, distribution and testing / certification company. Once the Company has obtained its Canadian Good Manufacturing ("GMP") license, CIPC plans to focus on applying GMP standards to generics manufactured outside of Canada so that these generics can be certified and tested on an ongoing basis as meeting Canadian standards. The Company also plans to utilize its anticipated

GMP license and its planned Canadian manufacturing facility to produce generics and neutraceuticals in Canada for the Canadian market. CIPC also plans to take advantage of international market demands for Canadian and US manufactured neutraceuticals and, in connection therewith, CIPC intends to negotiate and establish distribution agreements with Canadian and US neutraceuticals manufacturers.

For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030.

CANADIAN INTERNATIONAL PHARMA CORP.

"Douglas L. Mason"

____

Douglas L. Mason, Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this release.

FORWARD LOOKING STATEMENTS

This release includes certain statements that may be deemed "forward-looking statements" within the meaning of applicable securities legislation. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "suspects", "intends", "estimates", "projects", "targets", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in, or implied by, this forward looking information. Factors that could cause actual results to differ materially from those in forward-looking statements include such matters as market prices for the Company's anticipated products, regulatory approvals required for the Company's business plans, continued availability of capital and financing, and general economic, market or business conditions. Any forward-looking statements are expressly qualified in their entirety by this cautionary statement. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.